Sun Pharmaceutical Advanced Research Company Ltd is an international research based pharmaceutical company engaged in creating new drugs and delivery systems. The company works on innovation and new product development for global markets. They undertake projects in research and technology for new chemical entities (NCE`s) or new molecules, and novel drug delivery systems (NDDS).

The company designs and develops therapies for allergy and inflammation. They also designs and develops pro-drugs (chemical delivery systems) for marketed drugs that have poor oral absorption profile, which include Biodegradable implant or injection, Nanoemulsion, Dry Powder Inhalation Technology, Wrap Matrix Controlled Release Systems and Gastro Retentive System for Controlled Release.

The company`s SUN 1334 H is a novel antiallergic molecule, which is in phase II clinical trials in the United States. This is a selective histamine H1 receptor antagonist used for the therapy of allergic disorders such as seasonal and perennial allergic rhinitis, and urticaria. The company`s SUN-S 461 is an anti-inflammatory molecule for use in the treatment of asthma/ allergic rhinitis. SUN-44, a prodrug of gabapentin, is being successfully engineered as a gabapentin with improved pharmacokinetics.

Sun Pharmaceutical Advanced Research Company Ltd was formally created and deployed as a legal entity on March 1, 2006 as an innovative and development company. They commenced their operations on March 22, 2006. As per the scheme of arrangement, all the assets and liabilities of the Innovative Research & Development business including Novel Drug Delivery System (NDDS) division of Sun Pharmaceuticals Industries` Research & Development undertaking stands transferred and vested in the company with effect from the appointed date on February 28, 2007. The de-merger became effective on March 28, 2007. On the scheme being effective, the company ceased to be the subsidiary of Sun Pharmaceutical Industries Ltd, the de-merged company.

Pursuant to the scheme, the company issued and allotted 19,44,18,898 equity shares of Re 1 each to the equity shareholders of Sun Pharmaceutical Industries Ltd as on the record date, April 30, 2007. The equity shares of the company were listed on the Bombay Stock Exchange Ltd (BSE), and the National Stock Exchange of India Ltd with effect from 18 July, 2007.

During the year 2009-10, the Department of Scientific and Industrial Research (DSIR), Government of India sanctioned a 15 year unsecured soft loan under their Drug and Pharmaceutical Research Programme for a project of the company.

During 2011, the company announces USFDA approval for DOCEFREZ (docetaxel) for Injection". During 2012, the company delivers comprehensive solutions in rights issues to the share holders in the ration of 1:7. During 2014, the company announches Govt of India approval for Paclitaxel Injection Concentrate for Nanodispersion (PICN).